# CW-301 FIH Study of CAN016

Source: https://onco.cc/trials/nct07664150/  
OnCo record `nct07664150` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CAN016 in advanced solid tumours, run by Canwell Biotech Limited, now recruiting.

## Summary

CW-301 FIH Study of CAN016 is a phase 1/2 interventional study registered as NCT07664150 by Canwell Biotech Limited, with 90 participants planned, started 2026-06-18 and due to reach its primary completion in 2028-12-30. Interventions recorded: CAN016.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07664150
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients With Advanced Solid Tumors
- Sponsor: Canwell Biotech Limited
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07664150: https://clinicaltrials.gov/study/NCT07664150

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07664150.json